Blueprint Medicines Corp (BPMC)
$129.46
$0.00 (0.00%)As on 18-Jul-2025 09:30EDT
Market cap
$8,372 Mln
Revenue (TTM)
$562 Mln
P/E Ratio
--
P/B Ratio
24.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-10.1 %
-
Industry P/E
--
-
EV/EBITDA
-11.2
-
Debt to Equity
1
-
Book Value
$--
-
EPS
$-2.5
-
Face value
--
-
Shares outstanding
64,582,200
10 Years Aggregate
CFO
$-1,515.22 Mln
EBITDA
$-2,254.51 Mln
Net Profit
$-2,273.72 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Blueprint Medicines Corp (BPMC)
| 48.4 | 1.0 | 52.9 | 13.2 | 34.2 | 10.8 | 14.7 |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Midcap 400#
| 11.2 | -1.0 | -0.1 | 14.3 | 12.0 | 6.2 | 9.0 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Blueprint Medicines Corp (BPMC)
| -5.4 | 110.5 | -59.1 | -4.5 | 40.0 | 48.6 | -28.4 |
|
S&P Midcap 400
| 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 | -12.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Blueprint Medicines Corp (BPMC)
|
129.5 | 8,371.7 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.4 |
| 0.9 | 53.7 | 9.2 | -64.5 | -550.5 | -67.5 | -- | 0.7 | |
| 2.8 | 91.5 | 3.8 | -58.2 | -1,349.4 | -584.1 | -- | 7.9 |
Shareholding Pattern
View DetailsAbout Blueprint Medicines Corp (BPMC)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic... mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Read more
-
President, CEO & Director
Ms. Kathryn Haviland
-
President, CEO & Director
Ms. Kathryn Haviland M.B.A.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Blueprint Medicines Corp (BPMC)
What is the current share price of Blueprint Medicines Corp (BPMC) Today?
The share price of Blueprint Medicines Corp (BPMC) is $129.46 (NASDAQ) as of 18-Jul-2025 09:30 EDT. Blueprint Medicines Corp (BPMC) has given a return of 34.21% in the last 3 years.
What is the current PB & PE ratio of Blueprint Medicines Corp (BPMC)?
Since, TTM earnings of Blueprint Medicines Corp (BPMC) is negative, P/E ratio is not available.
The P/B ratio of Blueprint Medicines Corp (BPMC) is 24.44 times as on 18-Jul-2025, a 372 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-82.06 |
18.43 |
2023 |
-11.08 |
43.00 |
2022 |
-4.70 |
5.10 |
2021 |
-9.81 |
6.51 |
2020 |
20.03 |
4.28 |
What is the 52 Week High and Low of Blueprint Medicines Corp (BPMC)?
The 52-week high and low of Blueprint Medicines Corp (BPMC) are Rs -- and Rs -- as of 02-Sep-2026.
What is the market cap of Blueprint Medicines Corp (BPMC)?
Blueprint Medicines Corp (BPMC) has a market capitalisation of $ 8,372 Mln as on 18-Jul-2025. As per SEBI classification, it is a Mid Cap company.
Should I invest in Blueprint Medicines Corp (BPMC)?
Before investing in Blueprint Medicines Corp (BPMC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.